← All trials
NCT06334211
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2024
- Primary completion
- Sep 20, 2024
- Completion date
- Sep 20, 2024
- First posted
- Mar 27, 2024
- Last posted
- Oct 23, 2024
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Foresee Pharmaceuticals Co., Ltd.Lead sponsor
- InClin, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.